| Name | Title | Contact Details |
|---|
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
Clever Leaves is a multi-national cannabis company with a mission to operate in compliance with federal and state laws and with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade processing as the cornerstones of its global cannabinoid business. With operations and investments in Canada, Colombia, Germany, Portugal, and the United States, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry`s leading global cannabinoid companies recognized for its principles, people, and performance while fostering a healthier global community.
Headquartered in Louisville, Kentucky, with nearly $2 billion in annual revenues, PharMerica is one of the largest and fastest growing institutional pharmacy companies in America. We are a premier pharmacy services provider dedicated to providing innovative solutions for customers and patients. At PharMerica, you can choose your career path – hospital pharmacy, long term care pharmacy, corporate and non-clinical opportunities. We employ some of the industry`s best and brightest innovators and clinicians. With more than 100 long-term care pharmacies in over 45 states nationwide, PharMerica employs approximately 5,500 dedicated employees and pharmacy professionals. We offer our staff the opportunity to learn the business and cross train in other areas to provide a catalyst for their career growth within PharMerica. We also recruit our next generation of leaders by hiring new graduates from some of the nation`s top pharmacy and business schools. In addition, we offer educational opportunities through internships and our management training program. As a fast growing organization, we can provide you with the opportunity to kick start your career or advance your skills using some of the industry`s state-of-the-art technology. We foster an environment that encourages our high performers. Because we are a national company, we can provide opportunities for employees that desire to relocate. In addition, we offer a comprehensive benefits package that supports your quality of life.
Qserve is your MedTech Partner for Regulatory & Quality Affairs and Clinical Trials. Need regulatory advice, support or training? Contact us.
WellSpring Pharmaceutical Corporation is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.